1. “Clinical benefit” following treatment with antineoplastic drugs: What does it mean and how should we measure it?

   • Maurie Markman

   Editor’s Commentary Pages: 1 - 2

2. Web alert

   • William M. Sikov
   • Bassem M. Said

   News Pages: 3 - 5

3. Literature alert

   • Christy A. Russell

   Abstract Pages: 6 - 7

4. Update on metastatic breast cancer

   • Edith A. Perez

   Clinical Trials Review Pages: 11 - 15

5. The biology of human epidermal growth factor receptor 2

   • Srividya Sundaresan
   • Elicia Penuel
   • Mark X. Sliwkowski

   OriginalPaper Pages: 16 - 22

6. Dose-intensive chemotherapy for locally advanced breast cancer

   • Jolanda G. Schrama
   • Sjoerd Rodenhuis

   OriginalPaper Pages: 23 - 30

7. New data on adjuvant therapy for breast cancer

   • Antonio C. Wolff
   • Nancy E. Davidson

   OriginalPaper Pages: 31 - 37

8. Concurrent chemotherapy and radiation therapy in primary cancer of the cervix

   • Jeanne M. Schilder
   • Frederick B. Stehman

   OriginalPaper Pages: 41 - 46

9. Systemic therapy for advanced or recurrent endometrial carcinoma

   • Gini F. Fleming

   OriginalPaper Pages: 47 - 53

10. Dose-intensive approaches to ovarian cancer

    • Nicholas Lambrou
    • Edward L. Trimble

    OriginalPaper Pages: 54 - 58

11. Vascular endothelial growth factor in ovarian cancer

    • Darcie A. Hazelton
    • Thomas C. Hamilton

    OriginalPaper Pages: 59 - 63

12. Salvage therapy for ovarian cancer

    • Agustin A. Garcia

    OriginalPaper Pages: 64 - 70

13. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma

    • Alberto E. Selman
    • Larry J. Copeland

    OriginalPaper Pages: 71 - 76

14. In vitro chemosensitivity testing and mechanisms of drug resistance

    • Krishnansu Tewari
    • Alberto Manetta

    OriginalPaper Pages: 77 - 84